Formulary Search
You are here : Home > Formulary Search
A to Z of Drugs : R
Show Icon and Status Keys Hide Icon and Status Keys
Icon Key
Status Key
- Tablets
- Not Specified
- Not Specified
- Tablets
Off-label use. Specialist initiation and prescribing for at least 1 month before any request is made for primary care prescribing.
- Tablets
Only recommended as an option in secondary prevention where other options have been exhausted.
- Tablets
For post-exposure prophylaxis (e.g. needlestick injuries), follow your organisation's protocols for referral and access. Use as recommended by BHIVA/BASHH guidelines.
- Capsules
- Capsules
- Intravitreal injection
- Intravitreal injection
- Intravitreal injection
- Intravitreal injection
- Not Specified
- Modified release tablets
Restricted to cardiology
On recommendation from the specilist team
- Not Specified
- Tablets
- Intravenous infusion
Not on Surrey Heartlands Trust formularies. Trusts with renal centres (locally this is Epsom, Frimley & Brighton) will retain prescribing responsibility’.
Not on Surrey Heartlands Trust formularies. Trusts with renal centres (locally this is Epsom, Frimley & Brighton) will retain prescribing responsibility’.
- Not Specified
- Tablets
Specialist to prescribe at least 1 month treatment, prior to transfer of care
- Tablets
At least 1 month prescribing by the specialist prior to transfer of care.
A DXA scan is recommended after the first 52 weeks of treatment to verify that the patient does not have an unwanted degree of BMD loss, that exceeds the benefit of treatment. This DXA scan will be organised & performed by the specialist team responsible for the ongoing care of the patient
- Tablets
Specialist team initiation and at least 3 months of treatment prior to any request for primary care prescribing.
A DXA scan is recommended after the first 52 weeks of treatment
- Intravenous infusion
- Intravenous infusion
- Intravenous injection (IV)
1mg, 2mg, 5mg
- Intravenous injection (IV)
SASH Restriction: Adults Special Care Dentistry for indications below: - Frail older adults. - ASA3 medically complex patients, - Patients with severe cognitive disorders, - Complex oral surgery patients, - Patients with severe LD or ASD for whom a fast recovery makes care safer.
- Powder
Prescribe on advice from specialist e.g. dietitian
- Powder
Prescribe on advice from specialist e.g. dietitian
- Liquid
Prescribe on advice from specialist e.g. dietitian
- Powder
Prescribe on advice from specialist e.g. dietitian
- Tablets
On advice from specialist.
NHSE do not recommend the routine prescription of vitamins and mineral preparations, with the exceptions of patients with medically diagnosed deficiency, including those with lifelong or chronic conditions, or post surgery resulting in malabsorption (e.g. Whipple’s procedure and some other GI surgeries), calcium and vitamin D for osteoporosis, prescription-only vitamin D analogues or malnutrition. Continuing need should be reviewed on a regular basis. Not for use for prevention of deficiency
- Liquid
Prescribe on advice from specialist e.g. dietitian
- Tablets
- Not Specified
- Liquid
- Liquid
Altraplen Energy is the preferred second line 1.5kcal/ml supplement when required in primary care. Ready to drink supplements should only be prescribed if individual cannot prepare milkshake from powder.
- Powder
- Capsules
- Injection
- Oral solution
- Tablets
- Not Specified
- Capsules
- Not Specified
- Tablets
- Tablets
- Tablets
- Not Specified
- Tablets
- Oral suspension
- Orodispersible films
- Tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral lyophilisates
- Oral lyophilisates
- Not Specified
NHSE commissioned services only. No Surrey Heartlands Trusts are commissioned to provide this.
- Intravenous infusion
- Subcutaneous injection (sc)
- Not Specified
- Subcutaneous injection (sc)
- Tablets
Weekly tablets are 35mg. Daily tablets are 5mg.
NOTE - 30mg tablets are licensed for Paget's disease only
- Tablets
30mg tablets are licensed for Paget's disease.
- Oral solution
- Tablets
Licensed for up to 6 weeks in Alzheimer's dementia. On initiation, patients need a referal to SABP so that an assessment can be made at 6 weeks to weigh up response to treatment and benefit of treatment v risk of harm.
- Oro-dispersible tablets
Licensed for up to 6 weeks in Alzheimer's dementia. On initiation, patients need a referal to SABP so that an assessment can be made at 6 weeks to weigh up response to treatment and benefit of treatment v risk of harm.
Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.
- Tablets
Primary Care prescribing on advice from palliative care specialist team
- Oral solution
- Tablets
Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.
- Oral solution
- Tablets
For acute and chronic psychoses.
Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
For acute and chronic psychoses.
Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.
- Depot injection
For acute and chronic psychoses.
Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.
Only for continuation in existing patients.
- Capsules
SASH-Refer to SASH process on High Cost Drug internet page
- Tablets
- Not Specified
- Not Specified
- Not Specified
- Not Specified
Commissioned from RSFT only.
- Not Specified
- Injection
- Not Specified
- Not Specified
- Not Specified
- Intravenous infusion
Severe disease only
- Not Specified
- Not Specified
- Tablets
- Tablets
- Tablets
- Tablets
- Tablets
- Capsules
- Oral solution
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Patches
PATCHES - suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
SAFETY WARNING - patches are available as DAILY or TWICE WEEKLY but both are described in mg/24 hours. Care required to ensure that the intended patch is prescribed and dispensed.
An MHRA alert has also been issued in response to rivastigmine overdose due to multiple patch application, cutting patches and application of patches to non-recommended sites: https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors?UNLID=7961636092025721172155
- Not Specified
- Capsules
- Oral solution
In Lewy Body dementia. Off-label use.
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Patches
PATCHES - In Lewy Body dementia. Off-label use.
suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
SAFETY WARNING - patches are available as DAILY or TWICE WEEKLY but both are described in mg/24 hours. Care required to ensure that the intended patch is prescribed and dispensed.
An MHRA alert has also been issued in response to rivastigmine overdose due to multiple patch application, cutting patches and application of patches to non-recommended sites: https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors?UNLID=7961636092025721172155
- Capsules
- Oral solution
In Parkinson's dementia. Off-label use.
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Patches
PATCHES - In Parkinson's dementia. Off-label use.
suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
SAFETY WARNING - patches are available as DAILY or TWICE WEEKLY but both are described in mg/24 hours. Care required to ensure that the intended patch is prescribed and dispensed.
An MHRA alert has also been issued in response to rivastigmine overdose due to multiple patch application, cutting patches and application of patches to non-recommended sites: https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors?UNLID=7961636092025721172155
- Capsules
- Oral solution
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Patches
PATCHES - ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
SAFETY WARNING - patches are available as DAILY or TWICE WEEKLY but both are described in mg/24 hours. Care required to ensure that the intended patch is prescribed and dispensed.
An MHRA alert has also been issued in response to rivastigmine overdose due to multiple patch application, cutting patches and application of patches to non-recommended sites: https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors?UNLID=7961636092025721172155
- Not Specified
- Tablets
- Oro-dispersible tablets
- Oral lyophilisates
- Intravenous injection (IV)
- Tablets
- Subcutaneous injection (sc)
Haematology use only - treating chronic immune thrombocytopenia as per NICE TA221.
- Injection
- Immediate release tablets
- Modified release tablets
- Tablets
- Not Specified
- Injection
- Tablets
- Capsules
Rosuvastatin capsules are considerably more expensive and should not be prescribed.
- Patches
- Patches
- Tablets
Renal specialist teams only.
- Tablets
- Oral suspension
RSCH - only initiate on recommendation from a tertiary referral centre.
- Not Specified
- Cream